AUTHORS
Shruthi Suryaprakash, MD, Lei Han, PhD2, Garret Manquen3, Varun Katta4, Saicharan Akula, PhD5, Sukhmanjit Kaur, PhD6, Damian Krzyzanowski, PhD7, Jayaram Prasad8, Nikitha Nimmagada9, Kalin Mayberry10, Murali Reddivari11, Yan Ju12, Kelsey Ray, MS, MT(ASCP)13, Steven Ellis, PhD14, Marcin W Wlodarski, MD, PhD15, Shengdar Tsai, PhD16, Jonathan Yen, PhD17, Mitchell Weiss, MD, PhD18, Senthil Bhoopalan, MD PhD19
AFFILIATIONS
1 St. Jude Children's Research Hospital, Memphis, United States
2 St. Jude Children's Research Hospital, Memphis, United States
3 St. Jude Children's Research Hospital, Memphis, United States
4 St. Jude Children's Research Hospital, Memphis, United States
5 St. Jude Children's Research Hospital, Memphis, United States
6 St. Jude Children's Research Hospital, Memphis, United States
7 St. Jude Children's Research Hospital, Memphis, United States
8 St. Jude Children's Research Hospital, Memphis, United States
9 St. Jude Children's Research Hospital, Memphis, United States
10 St. Jude Children's Research Hospital, Memphis, United States
11 St. Jude Children's Research Hospital, Memphis, United States
12 St. Jude Children's Research Hospital, Memphis, United States
13 St. Jude Children's Research Hospital, Memphis, United States
14 University of Louisville, Louisville, United States
15 St. Jude Children's Research Hospital, Memphis, United States
16 St. Jude Children's Research Hospital, Memphis, United States
17 St. Jude Children's Research Hospital, Memphis, United States
18 St. Jude Children's Research Hospital, Memphis, United States
19 St. Jude Children's Research Hospital, Memphis, United States
ABSTRACT
Diamond-Blackfan anemia syndrome (DBAS) is an inherited bone marrow failure disorder characterized by hypoplastic anemia that presents in infancy. DBAS is caused by heterozygous loss-of-function mutations in one of 24 ribosomal protein genes, most commonly RPS19. Current therapies such as corticosteroids and red blood cell transfusions are suboptimal. Hematopoietic cell transplantation is curative, although many patients lack a suitable donor and/or develop toxicities such as graft-versus-host disease. We and others have shown the preclinical feasibility of lentiviral vector (LV) gene replacement therapy for DBAS. However, LVs cause DNA double-stranded breaks (DSBs) that transiently activate TP53, integrate semi-randomly into the genome, and can be genotoxic. Base editors (BEs) consisting of a Cas9 nickase fused to a deaminase domain cause precise nucleotide transitions (A·T to G·C or C·G to T·A) with minimal DSBs. This could be advantageous in DBAS, which is associated with increased TP53 activity at baseline. Preclinical studies assessing these approaches require large quantities of patient hematopoietic stem/progenitor cells (HSPCs), which are not easily available for practical and ethical reasons. Here we use two novel stem cell-based models to evaluate the preclinical safety and efficacy of adenine (A) BE (ABE8e) for correcting RPS19-mutated DBAS.
Induced pluripotent stem cells (iPSCs) are a robust model to study hematopoietic defects of DBAS (Garcon et al, Blood 2013). We recently established iPSCs from a DBAS patient with RPS19 c.184C>T (p.R62W) mutation and demonstrated a selective defect in erythropoiesis compared to an isogenic control line in which the causal mutation was corrected by homology-directed repair (Osuna et al, Stem Cell Res 2024; Suryaprakash et al, Blood Vol 144; 4088). We designed four different guide RNAs for mutation correction, mixed them separately with ABE8e, and electroporated the resultant ribonucleoprotein (RNP) complexes into the mutant iPSCs. Next-generation sequencing (NGS) of unedited control cells showed equal amounts of wild-type (c.184C) and mutant (c.184T) alleles in unedited cells, consistent with a heterozygous mutation. After base editing, the wild-type allele fraction increased to >90% (P<0.05) with three different sgRNAs, representing 80% correction of the mutant allele.
To assess the functional effects of genome editing, we generated iPSC-derived hematopoietic stem cells (iHSCs) using a recent protocol and incubated them under conditions to support erythroid differentiation in vitro (Ng et al., Nat Biotechnol, 2025). Base-edited DBA iHSCs showed a 6-fold increase in erythroid cell count and a 4-fold increase in CD235+CD71+ cells compared with unedited iHSCs (P<0.0001). Base editing of DBA iHSCs rescued characteristic molecular defects associated with DBAS, including ribosomal RNA processing defects measured by northern blot analysis and ribosomal dysbiogenesis measured by sucrose-gradient polysome profiling.
To evaluate editing of long-term engrafting HSCs, we used two approaches. First, mutant iHSCs were corrected with RNP and transplanted into NBSGW immunodeficient mice. After 16-18 weeks, recipient mouse bone marrow showed human cell chimerism of 21±24.8%. NGS showed a wild-type allele frequency of 95.4% in the edited input cells, which was maintained at 99.5±0.8% at 16 weeks post-transplant indicating robust editing in iHSCs.
Second, we used CRISPR/Cas9-mediated homology directed repair to introduce the RPS19 c.184C>T mutation into healthy donor CD34+ HSPCs, along with a synonymous RPS19 c.192G>C mutation to track manipulated cells. Approximately 28% of the HSPCs carried both mutations in cis. These HSPCs were subsequently treated with RNP to correct the pathogenic mutation. After editing, the fraction of pathogenic mutation decreased to 11%, while the tracking mutation was detected in 25.9%. Xenotransplantation experiments to determine whether the corrected CD34+ HSPCs outcompete uncorrected ones for bone marrow repopulation are ongoing.
Off-target analysis of base editing nominated 196 sites using CHANGE-Seq-BE (Lazzarotto et al, Nat Biotechnol 2026) and 667 sites by in silico analysis using Cas-OFFinder. Of these, 92 sites were nominated by both methods and are being validated. In summary, these studies show the feasibility of using novel hematopoietic stem cell models to accelerate preclinical development of genome editing for DBAS.
DISCLOSURES
Shruthi Suryaprakash, MD: No relevant conflicts of interest to declare.